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HelminthsSchistosomiasis is a neglected tropical disease caused by blood-dwelling ﬂukes of the genus Schistosoma.
While the disease may affect as many as 249 million people, treatment largely relies on a single drug, pra-
ziquantel. The near exclusive use of this drug for such a prevalent disease has led to concerns regarding
the potential for drug resistance to arise and the effect this would have on affected populations. In this
study, we use an in vitro assay of drug sensitivity to test the effect of praziquantel on miracidia hatched
from eggs obtained from fecal samples of Kenyan adult car washers and sand harvesters as well as school
children. Whereas in a previous study we found the car washers and sand harvesters to harbor Schisto-
soma mansoni with reduced praziquantel sensitivity, we found no evidence for the presence of such
strains in any of the groups tested here. Using miracidia derived from seven car washers to infect snails,
we used the shed cercariae to establish a strain of S. mansoniwith signiﬁcantly reduced praziquantel sen-
sitivity in mice. This was achieved within 5 generations by administering increasing doses of praziquantel
to the infected mice until the parasites could withstand a normally lethal dose. This result indicates that
while the threat of praziquantel resistance may have diminished in the Kenyan populations tested here,
there is a strong likelihood it could return if sufﬁcient praziquantel pressure is applied.
 2014 The Authors. Published by Elsevier Ltd. on behalf of Australian Society for Parasitology Inc. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction to cure infections due to its inability to kill juvenile schistosomes atSchistosomiasis is a water-borne parasitic disease that affects
more than 249 million people (World Health Organization, 2014)
with a global disease burden calculated at 24–56 million disabil-
ity-adjusted life-years lost (King, 2010). Of the limited number of
drugs available to treat schistosomiasis, praziquantel (PZQ) is the
least expensive and easiest to use (Hagan et al., 2004) and, since
PZQ is highly effective against all schistosome species that infect
humans, its use in mass treatment campaigns has grown signiﬁ-
cantly. In 2006, approximately 12 million people were treated with
PZQ and by 2012 this number reached approximately 42 million
(World Health Organization, 2014). While the drug is highly effec-
tive against sexually mature forms of the parasite it is often unable2–4 weeks post-infection (Pica-Mattoccia and Cioli, 2004; Aragon
et al., 2009). As PZQ is often administered with a signiﬁcant time
lapse measured in months or years between treatments this can
leave a signiﬁcant reservoir of schistosomes infecting people that
are unaffected by the drug. This, combined with continuing expo-
sure to the parasite, means the drug can often only provide short-
term relief from infection. Despite this drawback, PZQ remains the
only readily available treatment for schistosomiasis amid concern
that as it becomes more widely dispensed, drug resistance traits
may emerge thus removing the most effective, albeit ﬂawed drug
from the limited treatment options available.
There have been a number of in vivo and in vitro studies docu-
menting differential sensitivity of Schistosoma mansoni isolates to
PZQ. For example, a relatively low cure rate was reported during
a study of PZQ efﬁcacy and side effects in Senegal in 1991
(Stelma et al., 1995). A subsequent study of a ﬁeld isolate derived
from snails in the same geographical area suggested that, when
compared with two isolates from Puerto Rico and Kenya, the Sen-
egal isolate matured in mice at a signiﬁcantly slower rate thus
likely rendering it less susceptible to the drug at the times tested
(Fallon et al., 1997). Ismail et al. (1999) generated 12 S. mansoni
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that would normally prove effective. These isolates were main-
tained in mice and 8 were found to have a signiﬁcantly higher
ED50 than controls as well as a signiﬁcantly diminished contractile
response in vitro. In a related study, 3 of 6 isolates retained their
decreased response to PZQ after several passages through the life
cycle in the absence of PZQ (William et al., 2001). In addition, these
isolates had an associated diminished reproductive ﬁtness suggest-
ing reduced PZQ sensitivity may have come with a signiﬁcant bio-
logical cost. In a study using miracidial assays to determine PZQ
sensitivity, Lamberton et al. (2010) noted that S. mansoni hatched
from eggs obtained from the feces of children after two or more
PZQ treatments were more likely to survive in vitro exposure to
the drug compared with those from newly infected children.
Although this may point to a variation in susceptibility of adult S.
mansoni worm survival to repeated drug treatment, it may also
reﬂect differential susceptibility to PZQ of eggs at different stages
of maturity as they pass through the host. While treatment failure
has been reported in travellers returning from areas endemic for
Schistosoma haematobium (Mendonca da Silva et al., 2005; Alonso
et al., 2006), a study of individuals infected with S. haematobium
on Pemba Island, Tanzania found no indication of PZQ resistance
as determined by egg counts and miracidial viability after 20 years
of mass drug administration (Guidi et al., 2010).
Fallon and Doenhoff (1994) were able to induce PZQ resistance
in the laboratory by exposing a pool of S. mansoni isolates from
Puerto Rico, Brazil, Kenya and Egypt that had been maintained in
the laboratory for up to 10 years to increasing sub-curative doses
of PZQ. Mice infected with the 6th generation of selected cercariae
were then treated with 3  300 mg/kg doses at days 28, 35 and 37
after infection, and showed only a 7% reduction in worm burden
compared with an 88% reduction in mice infected with non-
selected worms. Coeli et al. (2013) infected mice with S. mansoni
(LE strain) and treated with PZQ following a protocol based on
Fallon and Doenhoff (1994) to generate worms with similarly
reduced drug sensitivity. This led to a decrease in genetic heteroge-
neity suggesting that multi-generational PZQ exposure resulted in
reduced population diversity. When schistosomes of the drug-
selected strain were bred with those of an unselected strain, the
F1 offspring were found to have intermediate PZQ sensitivity sug-
gesting the reduced susceptibility trait was co-dominant (Pica-
Mattoccia et al., 2009). Couto et al. (2011) were able to generate
S. mansoniwith reduced PZQ susceptibility within a single life cycle
by feeding PZQ to snails harboring the parasite.
Clearly, while studies of PZQ resistance have to take into account
confounding factors such as the rate of schistosomematurity aswell
as individual variations in drug metabolism and immune compe-
tency, thedevelopment of reduced susceptibility to PZQ is a real pos-
sibility. Here, we examine the in vitro susceptibility of miracidia
hatched from eggs derived from fecal samples of patients living in
two regions of Kenya endemic for schistosomiasis. In addition, we
used some of these miracidia to establish an S. mansoni laboratory
isolate with signiﬁcantly reduced susceptibility to PZQ.ðMean No: live miracidia from control groupÞ  ðMean No: live miracidia from treated groupÞ  100
Mean No: live miracidia from control group2. Materials and methods
2.1. S. mansoni egg collection from fecal samples of infected
individuals to obtain miracidia
Isolates of S. mansoni were recovered from eggs in fecal sam-
ples of adults working as car washers or sand harvesters inKisumu, western Kenya. Both groups spend signiﬁcant periods
of time in the water of Lake Victoria or the surrounding streams
as part of their occupation. All adults enrolled for this study came
from one of these two groups and all had previously been treated
with PZQ with the year of last treatment being between 2006 and
2013.
From 2004 to 2007, collaboration between the Kenya Medi-
cal Research Institute (KEMRI) and Japan International Coopera-
tion Agency administered a school-based schistosomiasis and
soil-transmitted helminth control project in Mwea, central
Kenya. The project dispensed annual doses of dewormers
including PZQ to all school-aged children in the region regard-
less of their infection status. Thereafter, the National Dewor-
ming Program took over the control activities, and has
continued with annual treatment of children since 2012 to date.
In this study, enrolled students were between 5 and 16 years of
age and were from three primary schools: Thiba, MbuiNjeru
and Mukou. Children were sampled in June 2013 or February
2014 with the date of last treatment within 1 year of sample
collection.
Fecal samples were tested for S. mansoni eggs using the modi-
ﬁed Kato Katz technique. Miracidia obtained from eggs in positive
fecal samples from individual patients were used to estimate their
in vitro sensitivity to PZQ and to establish a line of S. mansoni with
reduced sensitivity to PZQ.
The KEMRI Scientiﬁc and Ethical Committees and the Institu-
tional Review Board of the University of NewMexico approved this
study. All adults and the parents or guardians of the children
involved provided informed consent.
2.2. PZQ susceptibility assay of miracidia derived from fecal samples
Miracidial sensitivity to PZQ was tested in vitro using a modiﬁed
version of the technique developed by Liang et al. (2001). Freshly
hatched miracidia derived from stools of sand harvesters (n = 24),
car washers (n = 14) or school children (n = 34) were placed in each
well (4–6 miracidia per well) of a 96-well microtitre plate in 40 ll
aged tap water. Each row represented a single group of miracidia
and received either 0, 106 or 105 M PZQ. PZQ was prepared as
a stock solution of 104 M in 1% DMSO and the ﬁnal concentration
of DMSO was 0.1% in all wells including the control. The mean
number of groups of miracidia used per patient per concentration
of PZQ was 19.2 (range: 6–42). This was dependent on the number
of miracidia obtained from a fecal sample. Miracidia were observed
with a dissecting microscope prior to (0 min) and 20 min after the
addition of PZQ. An independent observer, who had no knowledge
of the miracidial source or PZQ concentration used, recorded the
number of dead miracidia. Miracidia were assumed dead if they
remained immobile. The percentage of miracidia mortality after
treatment for 20 min with 106 and 105 M PZQ was calculated
as follows:2.3. Snail sampling and parasite propagation in mice
In addition to testing PZQ sensitivity of S. mansoni miracidia
from parasite eggs of naturally infected individuals, miracidia
derived from cercariae shed from naturally infected, ﬁeld-collected
Biomphalaria snails were also tested after passage through
laboratory mice. Biomphalaria spp. were collected from sites where
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shores at Kisumu and Asao stream, both in western Kenya as well
as Kibwezi stream in southern Kenya and the Mukou and Nice Rice
irrigation ditches at Mwea, in central Kenya. Snails were washed
and separated into 24-well plates with aged tap water for up to
3 days with intermittent inspection for the appearance of S. man-
soni cercariae using a dissecting microscope. Shedding snails were
pooled and approximately 100 cercariae were used to infect each
of 2–3 outbred mice. At 49 days post-infection, S. mansoni eggs
were obtained from the mouse livers and hatched in aged tap
water. PZQ sensitivity of hatched miracidia was assessed using
the assay outlined above.
All animal experimentation complied with the policies, regula-
tions and guidelines mandated by the Institutional Animal Care
and Use Committees of the University of New Mexico and KEMRI.
2.4. Generation of an S. mansoni laboratory strain with reduced PZQ
susceptibility
Miracidia were hatched from eggs retrieved from fecal samples
obtained from 7 car washers and combined. This pool was used to
infect Biomphalaria sudanica and the cercariae shed subsequently
used to infect outbred mice. An isolate with reduced sensitivity
to PZQ was established after 5 generations with exposure to
increasing doses of PZQ essentially as described by Fallon and
Doenhoff (1994) with the following differences. Brieﬂy, 10 outbred
mice were infected with approximately 100 cercariae and ran-
domly distributed into two groups and treated with either
100 mg/kg/day PZQ in 2.5% Cremophor EL (Sigma, USA) (n = 5) or
an equivalent volume of 2.5% Cremophor EL vehicle alone (n = 5)
on each of days 28 and 35 post infection. 3 weeks after the ﬁnal
dose of PZQ or vehicle, mice were perfused with RPMI medium
and the number of worms counted. Statistical analysis of differ-
ences in worm yield from PZQ treated and vehicle treated mice
was calculated using an unpaired Student’s t-test assuming equal
variance.
For each passage, eggs from the liver that survived PZQ treat-
ment (selected) or vehicle treatment (non-selected) were used to
infect B. sudanica and the cercariae subsequently used to infect
the next generation of mice. This protocol was repeated for the sec-
ond passage with the dose of PZQ being increased to 200 and
250 mg/kg/day for the third and fourth passages. Mice in the 5th
passage received 300 mg/kg/day on days 28, 35 and 37 post-infec-
tion. In addition, mice infected with non-selected S. mansoni
received 2  200 and 2  250 mg/kg PZQ on days 28 and 35 post-
infection (passages 3 and 4) and 3  300 mg/kg PZQ on days 28,
35 and 37 post-infection (passage 5) to establish lethality of the
drug at these concentrations for the isolates being selected upon.
PZQ sensitivity of hatched miracidia obtained after each
passage was assessed using the protocol described above.Table 1
In vitro susceptibility to PZQ of S. mansoni miracidia derived from eggs in patient fecal sam
Patient group and location No. of patients
sampled
Mean No. o
per patient
Car washers
Kisumu
14 8.4
(3–20)
Sand harvesters
Kisumu
24 4.7
(1–11)
School children
Mwea–MbuiNjera
11 3.8
(1–5)
School
children Mwea–Mukou
18 3.3
(1–5)
School children
Mwea–Thiba
5 3.8
(2–5)
Data shown as mean ± 1 standard deviation.Approximately 6 drug-selected miracidia were placed in each of
48 wells of a 96 well microtitre plate. Twenty four wells were trea-
ted with 105 M PZQ and an additional 24 with the same volume of
PZQ vehicle and observed after 0 (pretreatment control), 10 and
20 min by an independent observer. Non-selected miracidia were
treated identically. The percentage of drug selected or non-selected
miracidia surviving at each time point after treatment was calcu-
lated as follows:
Mean No: live miracidia from PZQ treated group
Mean No: live miracidia from vehicle treated group
 100
Statistical analysis of miracidial survival was performed using
an unpaired Student’s t-test assuming unequal variance.
3. Results and discussion
In 2009, we (Melman et al., 2009) published a study measuring
PZQ sensitivity of S. mansoni miracidia hatched from eggs derived
from feces of adult Kenyan car washers and sand harvesters and
discovered there was a 2.42-fold increase in the chance that mira-
cidia would survive PZQ exposure if they were from individuals
previously treated with PZQ compared to untreated. Miracidia
derived from patients who had had between 4 and 20 PZQ treat-
ments showed mortality that ranged from 30 to over 80% when
exposed to 105 M PZQ in vitro, while the untreated cohort showed
mortality ranging from 60% to 100%. For this study we returned to
these occupational groups as well as a cohort of Kenyan school
children undergoing PZQ therapy to determine if there is signiﬁ-
cant variability in PZQ sensitivity of the S. mansoni population
infecting these individuals. In addition, we examined variation in
PZQ sensitivity of S. mansonimiracidia obtained frommice infected
with cercariae derived from naturally infected snail populations.
Fecal samples were obtained from a total of 72 individuals with
a history of treatment with PZQ. For the purpose of a direct control,
it was not possible to identify individuals within our patient
groups who had not received PZQ previously. Irrespective of the
patient group the mean miracidial mortality of S. mansoni at
105 M PZQ was between 82.1% and 84.6% with the lowest
observed value of miracidia from a single patient being 72.7%
(Table 1). As these data are comparable with the sensitivity of
miracidia derived from eggs of the untreated cohort in our 2009
study, it suggests there is no evidence of diminished PZQ sensitiv-
ity in S. mansoni infecting these populations. For the car washers
and sand harvesters, the last treatment dates were between 1
and 9 years before the current study and thus, it is perhaps not sur-
prising that, without sustained PZQ treatment, a population of S.
mansoni with reduced responsiveness to PZQ has failed to materi-
alize. In addition, there was no indication of reduced miracidial
susceptibility to PZQ among samples obtained from the 34 school
children that previously had between one and ﬁve PZQ treatmentsples.
f PZQ treatments
(range)
Mean% miracidial mortality (range)
106 M PZQ 105 M PZQ
26.1 ± 5.5
(17.7–33.3)
83.2 ± 4.2
(74.4–88.0)
21.4 ± 3.1
(17.2–25.3)
81.5 ± 4.8
(72.7–88.8)
27.4 ± 5.0
(19.4–32.1)
84.6 ± 4.8
(76.3–91.6)
27.0 ± 5.4
(19.4–39.8)
83.8 ± 4.5
(76.5–90.7)
25.4 ± 4.7
(21.0–32.5)
82.1 ± 3.7
(78.0 ± 82.6)
Table 2
Worms recovered from infected mice after treatment with PZQ during 5 passages of S.
mansoni.
Passage No. PZQ treatment
mg/kg
No. of worms
Mean ± SD
Male:female
ratio
1 2  Vehicle 48.0 ± 5.9* 1.8
2  100 37.2 ± 5.2 3.0
2 2  Vehicle 43.8 ± 7.7 2.6
2  100 41.0 ± 7.6 3.1
3 2  Vehicle 43.2 ± 4.6 1.5
2  200 36.4 ± 8.6 1.4
4 2  Vehicle 53.4 ± 4.2 1.5
2  250 49.6 ± 4.6 1.5
5 2  Vehicle 51.4 ± 1.7 1.3
3  300 50.2 ± 7.8 1.6
SD: 1 standard deviation.
* p < 0.05.
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ming Program. Similarly, when miracidia derived from mice
infected with cercariae from naturally infected snails collected in
Kisumu, Mwea and Kibwezi areas were tested, no evidence of
reduced susceptibility to PZQ was found (mortality at 105 M
PZQ = 82.3 ± 4.9%; range = 75.8–90.3%). Thus, using miracidia as
an indicator of S. mansoni sensitivity to PZQ in the deﬁnitive host
our data implies there is, as yet, no evidence to suggest that resis-
tance or even reduced sensitivity is an immediate threat in the
areas surveyed.
Administration of one round of PZQ treatment to school chil-
dren in Tanzania resulted in a signiﬁcant reduction in genetic
diversity of S. mansoni populations within the children (Norton
et al., 2010; French et al., 2013). While there are many reasons to
account for such genetic ‘bottlenecking’ after PZQ treatment, one
concern is it may lead to a greater likelihood of development of
PZQ resistant parasite strains. Clearly, at least in the case of S. man-
soni infecting the school children who took part in this study this
has not happened. A recent analysis of genetic variability of S. man-
soni in this cohort suggests there has been no reduction in schisto-
some burden and genetic diversity actually increased after 4 years
of mass drug administration (data not shown). This latter observa-
tion would be more in agreement with Huyse et al. (2013) who
reported that regular treatment with PZQ did not affect the genetic
diversity of S. mansoni in Senegal.
In recent years, PZQ treatment of car washers and sand harvest-
ers in Kisumu has become intermittent with the result that only a
small proportion of the infected population is undergoing treat-
ment at any one time. This would leave a signiﬁcant reservoir of
parasites unaffected by the drug and likely allow any S. mansoni
strain with reduced susceptibility to be lost from patients, espe-
cially if, as has been reported, an ability to withstand PZQ treat-
ment also carries a cost to reproductive ﬁtness (William et al.,
2001; Coeli et al., 2013). In order to determine if this population
still harbored the potential to generate S. mansoni with reduced
PZQ sensitivity, we used a mouse infection model to study the
impact of increasing amounts of PZQ on a population of parasites
derived from 7 car washers. During the ﬁrst and second passages,
mice were treated with 100 mg/kg PZQ on days 28 and 35 after
infection. After the ﬁrst passage there was a small but signiﬁcant
fall in the number of worms recovered after treatment with
100 mg/kg PZQ compared to vehicle treated controls and an
increase in the male to female ratio from 1.8 to 3.0 (Table 2). Dur-
ing passage 5, 3  300 mg/kg PZQ was administered to mice on
days 28, 35 and 37 after infection with no effect on worm numbers
or sex ratio compared with vehicle treated controls. In contrast,
treatment of mice infected with non-PZQ selected S. mansoni
during passages 3, 4 and 5 with 2  200, 2  250 and3  300 mg/kg PZQ respectively resulted in 36, 66 and 86% reduc-
tions in worm numbers compared to vehicle treated mice. This
data suggests that we were able to generate a PZQ isolate with
low susceptibility to a normally effective dose of PZQ and is in
close accordance with that of Fallon and Doenhoff (1994) who used
a number of laboratory strains of S. mansoni from geographically
diverse regions as the source of their genetic material. Sexually
mature female worms isolated from bisexual infections in mice
have been shown to be less sensitive to PZQ in vitro than mature
male worms
(Pica-Mattoccia et al., 2004) while Delgado et al. (1992) showed a
preferential killing of female worms in vivo. Despite some initial
selection for males in the ﬁrst round of PZQ treatment in the exper-
iment reported here we saw no subsequent evidence for the selec-
tion of either sex. Interestingly, in a similar experiment using S.
mansoni LE strain, Coeli et al. (2013) were also able to generate
an isolate that was able to withstand 3  300 mg/kg PZQ after 6
generations, but were unable to maintain the strain beyond the
11th generation under PZQ pressure due to a change in the male:
female ratio from 2.5 in treated, non-selected worms to 8.7 in trea-
ted, PZQ selected worms suggesting that female worms of the LE
strain are more susceptible to PZQ after repeated exposure and
selection. We will continue to passage our selected S. mansoni
strain to determine if heightened female sensitivity to PZQ
reported by Coeli et al. (2013) is due to the use of a laboratory
strain as the founder population or whether a more genetically
diverse founder population leads to a more stable long-term sex
ratio.
Miracidia hatched from livers of PZQ and vehicle treated mice
during each passage were assayed for their ability to survive PZQ
treatment in vitro (Fig. 1). Our data suggests that miracidia pro-
duced by drug-selected S. mansoni are also less susceptible to the
drug, especially during the 4th and 5th passage suggesting that
acquired resistance may be a heritable trait.
We have shown that a cohort of 72 adults and children living in
endemic areas of western and central Kenya who have undergone
recent or historical treatment with PZQ do not harbor S. mansoni
with reduced PZQ susceptibility. Nonetheless, while schistosomes
with a ‘resistant’ phenotype may not be problematic within these
populations, we have also shown there is a signiﬁcant potential
for the emergence of such a phenotype should sufﬁcient PZQ pres-
sure be applied. It is fortuitous that with perhaps only approxi-
mately 15% of people with schistosomiasis being treated with
PZQ together with the intermittent nature of much of that treat-
ment, a large refugium for drug sensitive parasites will continue
to exist. This, together with apparent ﬁtness costs associated with
PZQ resistance (William et al., 2001; Coeli et al., 2013), may well
prevent the near-term establishment of drug resistant strains in
the human population. The far-term prospects for keeping resis-
tance at bay are more worrisome. In 2012, the WHO announced
a ‘roadmap’ for the elimination of 17 neglected tropical diseases
(NTD) (World Health Organization, 2012), one of which was schis-
tosomiasis. It was proposed that the disease could be eliminated as
a public health problem in multiple African countries by 2020 and
globally by 2025. This in turn inspired a global alliance of 22 part-
ners including the WHO, The Bill and Melinda Gates Foundation,
World Bank and major pharmaceutical companies to announce
through the 2012 ‘London Declaration’ a sustained program to
‘control’ schistosomiasis by 2020 (http://unitingtocombatntds.
org). While 42 million PZQ tablets were dispensed in 2012
(World Health Organization, 2014) this number is likely to increase
greatly in the near future to meet the immediate goal of disease
control. Merck KgaA will make 250 million PZQ tablets per year
freely available in the medium-term and, with other manufactur-
ers expected to contribute tablets to help bridge the expected
shortfall in supply, there are signiﬁcant grounds for concern that
Fig. 1. In vitro efﬁcacy of 105 M PZQ in killing PZQ selected and non-selected S. mansoni miracidia. Mice infected with S. mansoni were treated with the indicated doses of
PZQ over 5 passages (selected) or PZQ vehicle alone (non-selected). The survival of the selected (j) and non-selected (}) miracidia treated with 105 M PZQ was calculated as
a percentage of vehicle treated controls at each time point. Data shown as mean + 1 SD (⁄p < 0.05; ⁄⁄p < 0.01; ⁄⁄⁄p < 0.001).
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close monitoring of drug efﬁcacy should have an important role to
play as control efforts are ramped up in the coming years.
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